Dr. Deborah Donnell: A new long-acting PrEP regimen holds promise to transform the landscape of HIV prevention.

Dr. Deborah Donnell: A new long-acting PrEP regimen holds promise to transform the landscape of HIV prevention.

In 2021, the United Nations set forth the goal of "ending the AIDS epidemic by 2030". To achieve this, not only must countries strengthen the diagnosis and treatment of HIV infections, but they also need to prioritize prevention to minimize the emergence of new infections. Pre-Exposure Prophylaxis (PrEP) long-acting regimens have become a recent focal point in HIV prevention. At the recently held 12th International AIDS Society HIV Science Conference (IAS 2023), there were several keynote lectures on the topic of long-acting PrEP.
Dr. Ana Hoxha: Clinical characteristics and outcomes of MPXV and HIV co-infected patients

Dr. Ana Hoxha: Clinical characteristics and outcomes of MPXV and HIV co-infected patients

In 2022, about 70 countries/regions around the world reported cases of MPOX. These countries/regions usually have no prior history of MPXV infections, and previous sustained human-to-human transmissions of MPXV were mainly observed in Africa. At the recent 12th International AIDS Society HIV Science Conference (IAS 2023), Dr. Ana Hoxha from the World Health Organization (WHO) presented a special report titled "HIV among MPOX cases: clinical characteristics and outcomes in the WHO global surveillance 2022".
Exploring New Breast Cancer Risk Genes, Biomarkers, and Prognostic Models at AACR 2023

Exploring New Breast Cancer Risk Genes, Biomarkers, and Prognostic Models at AACR 2023

The American Association for Cancer Research (AACR) held its annual conference from April 14th to 19th, 2023 in Orlando, USA. With numerous reports on clinical, fundamental, and translational cancer research presented each year, this year's AACR conference delved deep into the realm of breast cancer. Research focused on the analysis of various susceptibility genes and risk-related biomarkers, aiming to discover new therapeutic targets and develop prognostic models, with the hope of providing improved services for patients.
New Data on KRAS G12C Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer

New Data on KRAS G12C Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer

The 2023 annual meeting of the American Association for Cancer Research (AACR) was held in Orlando, USA, from April 14th to 19th, 2023. Various important basic and clinical research results were presented at the conference, including the latest results of a Phase I study of IBI351 monotherapy in patients with advanced solid tumors from China. According to the latest data from this Phase I dose-escalation study (NCT05005234), the Phase II recommended dose of IBI351 monotherapy for advanced KRAS G12C mutated non-small cell lung cancer (NSCLC) patients shows good safety and promising efficacy.
Progress of ctDNA in predicting prognosis of patients with urological tumors

Progress of ctDNA in predicting prognosis of patients with urological tumors

Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was held from April 14 to 19, 2023, in Orlando, USA. In this AACR conference, three ctDNA-related studies evaluated its application value in urological tumors.
KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract Cancer Patients

KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract Cancer Patients

According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this approach demonstrated consistent survival benefits across geographical regions and PD-L1 expression subgroups. The KEYNOTE-966 study results were concurrently published in "The Lancet."
Innovative Chinese Immunotherapy, Sintilimab Sets New Survival Records for Upper Gastrointestinal Cancers

Innovative Chinese Immunotherapy, Sintilimab Sets New Survival Records for Upper Gastrointestinal Cancers

At the 2023 American Association for Cancer Research (AACR) annual meeting held on April 17, groundbreaking long-term follow-up data from studies on the Chinese innovative PD-1 inhibitor, Sintilimab, was unveiled. The findings span from phase III clinical trials for esophageal cancer (ORIENT-15) and gastric cancer (ORIENT-16). The results from these trials have set new longevity records for first-line treatments of these cancers in China.
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.
Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation

Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation

The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer; The CHHiP study further reports survival and comorbidity outcomes with a 12-year follow-up.
Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer

Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer

Advanced urothelial cancer (aUC) has seen remarkable progress in recent years with the emergence of antibody-drug conjugates (ADCs) targeting specific antigens. Trop-2, a cell surface antigen highly expressed in UC, has become a promising therapeutic target. Sacituzumab govitecan (SG), a next-generation Trop-2 ADC, received accelerated approval from the US FDA in April 2021 for treating adult patients with locally advanced or metastatic UC who had prior platinum-based chemotherapy and PD-(L)1 inhibitors. The 2023 ASCO-GU conference unveiled data from various cohorts of the TROPHY-U-01 trial and the latest advancements in UC treatment, encompassing late-line monotherapy, combination therapy, first-line combination therapy, and first-line maintenance therapy. Here, we summarize essential findings from these presentations, anticipating further insights after the conference.